siRNA and RNAi optimization

Wiley Interdisciplinary Reviews: RNA

Volumn 7, Issue 3, 2016, Pages 316-329

  Alagia, Adele ^a   Eritja, Ramon ^a  

^a BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; MICRORNA; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; PIWI PROTEIN; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; BIOLOGICAL PRODUCT;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; APOPTOSIS; CATALYSIS; CELL POPULATION; CONFORMATIONAL TRANSITION; CYTOSOL; DOWN REGULATION; GENE SILENCING; HUMAN; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RETICULOENDOTHELIAL SYSTEM; REVIEW; RNA CLEAVAGE; RNA DEGRADATION; RNA INTERFERENCE; RNA RNA HYBRIDIZATION; RNA STRUCTURE; UPREGULATION; METABOLISM;

BIOLOGICAL PRODUCTS; HUMANS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84959036971     PISSN: 17577004     EISSN: 17577012     Source Type: Journal    
DOI: 10.1002/wrna.1337     Document Type: Review

References (127)

1. Howard KA . RNA Interference from Biology to Therapeutics. Springer; 2013, 340.
2. Taxman DJ . siRNA Design: Methods and Protocols. Humana Press; 2012, 392.
3. Cheng K, Mahato RI . Advanced Delivery and Therapeutic Applications of RNAi. Wiley; 2013, 543.
4. Meares CF, Yokoyama M . Special issue on gene silencing and delivery. Acc Chem Res 2012, 45:959-1171.
5. Burnett JC, Rossi JJ . RNA-based therapeutics: current progress and future prospects. Chem Biol 2012, 19:60-71.
6. Chakraborty C . Potentiality of small interfering RNAs (siRNA) as recent therapeutic targets for gene-silencing. Curr Drug Targets 2007, 8:469-482.
7. Siomi H, Siomi MC . On the road to reading the RNA-interference code. Nature 2009, 457:396-404.
8. Shukla S, Sumaria CS, Pradeepkumar PI . Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook. ChemMedChem 2010, 5:328-349.
9. Stanton MG, Colletti SL . Medicinal chemistry of siRNA delivery. J Med Chem 2010, 53:7887-7901.
10. Napoli C, Lemieux C, Jorgensen R . Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990, 2:279-289.
11. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC . Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans . Nature 1998, 391:806-811.
12. Hammond SM, Bernstein E, Beach D, Hannon GJ . An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000, 404:293-296.
13. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, Hannon GJ . Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004, 305:1437-1441.
14. Hamilton AJ, Baulcombe DC . A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 1999, 286:950-952.
15. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T . Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
16. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS . Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003, 21:635-637.
17. Chang CI, Kim HA, Dua P, Kim S, Li CJ, Lee DK . Structural diversity repertoire of gene silencing small interfering RNAs. Nucleic Acid Ther 2011, 21:125-131.
18. Tafer H . Bioinformatics of siRNA design. Methods Mol Biol 2014, 1097:477-490.
19. Tafer H, Ameres SL, Obernosterer G, Gebeshuber CA, Schroeder R, Martinez J, Hofacker IL . The impact of target site accessibility on the design of effective siRNAs. Nat Biotechnol 2008, 26:578-583.
20. Ameres SL, Martinez J, Schroeder R . Molecular basis for target RNA recognition and cleavage by human RISC. Cell 2007, 130:101-112.
21. Deleavey GF, Damha MJ . Designing chemically modified oligonucleotides for targeted gene silencing. Chem Biol 2012, 19:937-954.
22. Grijalvo S, Avino A, Eritja R . Oligonucleotide delivery: a patent review (2010-2013). Expert Opin Ther Pat 2014, 24:801-819.
23. Meister G . Argonaute proteins: functional insights and emerging roles. Nat Rev Genet 2013, 14:447-459.
24. Frank F, Sonenberg N, Nagar B . Structural basis for 5'-nucleotide base-specific recognition of guide RNA by human AGO2. Nature 2010, 465:818-822.
25. Wang HW, Noland C, Siridechadilok B, Taylor DW, Ma E, Felderer K, Doudna JA, Nogales E . Structural insights into RNA processing by the human RISC-loading complex. Nat Struct Mol Biol 2009, 16:1148-1153.
26. Song JJ, Liu J, Tolia NH, Schneiderman J, Smith SK, Martienssen RA, Hannon GJ, Joshua-Tor L . The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes. Nat Struct Biol 2003, 10:1026-1032.
27. Kwak PB, Tomari Y . The N domain of Argonaute drives duplex unwinding during RISC assembly. Nat Struct Mol Biol 2012, 19:145-151.
28. Jinek M, Doudna JA . A three-dimensional view of the molecular machinery of RNA interference. Nature 2009, 457:405-412.
29. Rana TM . Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007, 8:23-36.
30. Wee LM, Flores-Jasso CF, Salomon WE, Zamore PD . Argonaute divides its RNA guide into domains with distinct functions and RNA-binding properties. Cell 2012, 151:1055-1067.
31. Schirle NT, Sheu-Gruttadauria J, MacRae IJ . Structural basis for microRNA targeting. Science 2014, 346:608-613.
32. Lima WF, Wu H, Nichols JG, Sun H, Murray HM, Crooke ST . Binding and cleavage specificities of human Argonaute2. J Biol Chem 2009, 284:26017-26028.
33. Felice KM, Salzman DW, Shubert-Coleman J, Jensen KP, Furneaux HM . The 5' terminal uracil of let-7a is critical for the recruitment of mRNA to Argonaute2. Biochem J 2009, 422:329-341.
34. Boland A, Tritschler F, Heimstadt S, Izaurralde E, Weichenrieder O . Crystal structure and ligand binding of the MID domain of a eukaryotic Argonaute protein. EMBO Rep 2010, 11:522-527.
35. Schirle NT, Sheu-Gruttadauria J, Chandradoss SD, Joo C, MacRae IJ . Water-mediated recognition of t1-adenosine anchors Argonaute2 to microRNA targets. Elife 2015, 4:e07646.
36. Onizuka K, Harrison JG, Ball-Jones AA, Ibarra-Soza JM, Zheng Y, Ly D, Lam W, Mac S, Tantillo DJ, Beal PA . Short interfering RNA guide strand modifiers from computational screening. J Am Chem Soc 2013, 135:17069-17077.
37. Wang Y, Juranek S, Li H, Sheng G, Wardle GS, Tuschl T, Patel DJ . Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes. Nature 2009, 461:754-761.
38. Wang X . Composition of seed sequence is a major determinant of microRNA targeting patterns. Bioinformatics 2014, 30:1377-1383.
39. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, Linsley PS . Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 2006, 12:1179-1187.
40. Ui-Tei K . Optimal choice of functional and off-target effect-reduced siRNAs for RNAi therapeutics. Front Genet 2013, 4:107.
41. Ui-Tei K, Naito Y, Nishi K, Juni A, Saigo K . Thermodynamic stability and Watson-Crick base pairing in the seed duplex are major determinants of the efficiency of the siRNA-based off-target effect. Nucleic Acids Res 2008, 36:7100-7109.
42. Bramsen JB, Pakula MM, Hansen TB, Bus C, Langkjaer N, Odadzic D, Smicius R, Wengel SL, Chattopadhyaya J, Engels JW, et al. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res 2010, 38:5761-5773.
43. Gu S, Zhang Y, Jin L, Huang Y, Zhang F, Bassik MC, Kampmann M, Kay MA . Weak base pairing in both seed and 3' regions reduces RNAi off-targets and enhances si/shRNA designs. Nucleic Acids Res 2014, 42:12169-12176.
44. Vaish N, Chen F, Seth S, Fosnaugh K, Liu Y, Adami R, Brown T, Chen Y, Harvie P, Johns R, et al. Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res 2011, 39:1823-1832.
45. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, Nichols K, et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006, 12:1197-1205.
46. Ui-Tei K, Naito Y, Zenno S, Nishi K, Yamato K, Takahashi F, Juni A, Saigo K . Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res 2008, 36:2136-2151.
47. Schirle NT, MacRae IJ . The crystal structure of human Argonaute2. Science 2012, 336:1037-1040.
48. Kume H, Hino K, Galipon J, Ui-Tei K . A-to-I editing in the miRNA seed region regulates target mRNA selection and silencing efficiency. Nucleic Acids Res 2014, 42:10050-10060.
49. Sipa K, Sochacka E, Kazmierczak-Baranska J, Maszewska M, Janicka M, Nowak G, Nawrot B . Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. RNA 2007, 13:1301-1316.
50. Chak LL, Okamura K . Argonaute-dependent small RNAs derived from single-stranded, non-structured precursors. Front Genet 2014, 5:172.
51. Leuschner PJ, Ameres SL, Kueng S, Martinez J . Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep 2006, 7:314-320.
52. Gu S, Jin L, Huang Y, Zhang F, Kay MA . Slicing-independent RISC activation requires the argonaute PAZ domain. Curr Biol 2012, 22:1536-1542.
53. Takahashi T, Zenno S, Ishibashi O, Takizawa T, Saigo K, Ui-Tei K . Interactions between the non-seed region of siRNA and RNA-binding RLC/RISC proteins, Ago and TRBP, in mammalian cells. Nucleic Acids Res 2014, 42:5256-5269.
54. Zheng J, Zhang L, Zhang J, Wang X, Ye K, Xi Z, Du Q, Liang Z . Single modification at position 14 of siRNA strand abolishes its gene-silencing activity by decreasing both RISC loading and target degradation. FASEB J 2013, 27:4017-4026.
55. Prakash TP, Allerson CR, Dande P, Vickers TA, Sioufi N, Jarres R, Baker BF, Swayze EE, Griffey RH, Bhat B . Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem 2005, 48:4247-4253.
56. Alagia A, Terrazas M, Eritja R . Modulation of the RNA interference activity using central mismatched siRNAs and acyclic threoninol nucleic acids (aTNA) units. Molecules 2015, 20:7602-7619.
57. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T . Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001, 20:6877-6888.
58. Deerberg A, Willkomm S, Restle T . Minimal mechanistic model of siRNA-dependent target RNA slicing by recombinant human Argonaute 2 protein. Proc Natl Acad Sci USA 2013, 110:17850-17855.
59. Zander A, Holzmeister P, Klose D, Tinnefeld P, Grohmann D . Single-molecule FRET supports the two-state model of Argonaute action. RNA Biol 2014, 11:45-56.
60. Alagia A, Terrazas M, Eritja R . RNA/aTNA chimeras: RNAi effects and nucleases resistance of single and double stranded RNAs. Molecules 2014, 19:17872-17896.
61. Terrazas M, Ocampo SM, Perales JC, Marquez VE, Eritja R . Effect of north bicyclo[3.1.0]hexane 2'-deoxy-pseudosugars on RNA interference: a novel class of siRNA modification. Chembiochem 2011, 12:1056-1065.
62. Potenza N, Moggio L, Milano G, Salvatore V, Di Blasio B, Russo A, Messere A . RNA interference in mammalia cells by RNA-3'-PNA chimeras. Int J Mol Sci 2008, 9:299-315.
63. Kamiya Y, Takai J, Ito H, Murayama K, Kashida H, Asanuma H . Enhancement of stability and activity of siRNA by terminal substitution with serinol nucleic acid (SNA). Chembiochem 2014, 15:2549-2555.
64. Terrazas M, Alagia A, Faustino I, Orozco M, Eritja R . Functionalization of the 3'-ends of DNA and RNA strands with N-ethyl-N-coupled nucleosides: a promising approach to avoid 3'-exonuclease-catalyzed hydrolysis of therapeutic oligonucleotides. Chembiochem 2013, 14:510-520.
65. Gaglione M, Potenza N, Di Fabio G, Romanucci V, Mosca N, Russo A, Novellino E, Cosconati S, Messere A . Tuning RNA interference by enhancing siRNA/PAZ recognition. ACS Med Chem Lett 2013, 4:75-78.
66. Somoza A, Terrazas M, Eritja R . Modified siRNAs for the study of the PAZ domain. Chem Commun (Camb) 2010, 46:4270-4272.
67. Kandeel M, Kitade Y . In silico molecular docking analysis of the human Argonaute 2 PAZ domain reveals insights into RNA interference. J Comput Aided Mol Des 2013, 27:605-614.
68. Zhou J, Song MS, Jacobi AM, Behlke MA, Wu X, Rossi JJ . Deep sequencing analyses of DsiRNAs reveal the influence of 3' terminal overhangs on dicing polarity, strand selectivity, and RNA editing of siRNAs. Mol Ther Nucleic Acids 2012, 1:e17.
69. Xu L, Wang X, He H, Zhou J, Li X, Ma H, Li Z, Zeng Y, Shao R, Cen S, et al. Structure-based design of novel chemical modification of the 3'-overhang for optimization of short interfering RNA performance. Biochemistry 2015, 54:1268-1277.
70. Sano M, Sierant M, Miyagishi M, Nakanishi M, Takagi Y, Sutou S . Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection. Nucleic Acids Res 2008, 36:5812-5821.
71. Hoerter JA, Krishnan V, Lionberger TA, Walter NG . siRNA-like double-stranded RNAs are specifically protected against degradation in human cell extract. PLoS One 2011, 6:e20359.
72. Bartlett DW, Davis ME . Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 2006, 34:322-333.
73. Bartlett DW, Davis ME . Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng 2007, 97:909-921.
74. Bramsen JB, Kjems J . Development of therapeutic-grade small interfering RNAs by chemical engineering. Front Genet 2012, 3:154.
75. Snead NM, Wu X, Li A, Cui Q, Sakurai K, Burnett JC, Rossi JJ . Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants. Nucleic Acids Res 2013, 41:6209-6221.
76. Abe N, Abe H, Nagai C, Harada M, Hatakeyama H, Harashima H, Ohshiro T, Nishihara M, Furukawa K, Maeda M, et al. Synthesis, structure, and biological activity of dumbbell-shaped nanocircular RNAs for RNA interference. Bioconjug Chem 2011, 22:2082-2092.
77. Bramsen JB, Laursen MB, Damgaard CK, Lena SW, Babu BR, Wengel J, Kjems J . Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res 2007, 35:5886-5897.
78. Chang CI, Yoo JW, Hong SW, Lee SE, Kang HS, Sun X, Rogoff HA, Ban C, Kim S, Li CJ, et al. Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther 2009, 17:725-732.
79. Sun X, Rogoff HA, Li CJ . Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat Biotechnol 2008, 26:1379-1382.
80. Yuan Z, Wu X, Liu C, Xu G, Wu Z . Asymmetric siRNA: new strategy to improve specificity and reduce off-target gene expression. Hum Gene Ther 2012, 23:521-532.
81. Lima WF, Prakash TP, Murray HM, Kinberger GA, Li W, Chappell AE, Li CS, Murray SF, Gaus H, Seth PP, et al. Single-stranded siRNAs activate RNAi in animals. Cell 2012, 150:883-894.
82. Kenski DM, Cooper AJ, Li JJ, Willingham AT, Haringsma HJ, Young TA, Kuklin NA, Jones JJ, Cancilla MT, McMasters DR, et al. Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5'-terminal phosphorylation both in vitro and in vivo. Nucleic Acids Res 2010, 38:660-671.
83. Chen PY, Weinmann L, Gaidatzis D, Pei Y, Zavolan M, Tuschl T, Meister G . Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 2008, 14:263-274.
84. Snead NM, Escamilla-Powers JR, Rossi JJ, McCaffrey AP . 5' Unlocked nucleic acid modification improves siRNA targeting. Mol Ther Nucleic Acids 2013, 2:e103.
85. Tiemann K, Hohn B, Ehsani A, Forman SJ, Rossi JJ, Saetrom P . Dual-targeting siRNAs. RNA 2010, 16:1275-1284.
86. Hossbach M, Gruber J, Osborn M, Weber K, Tuschl T . Gene silencing with siRNA duplexes composed of target-mRNA-complementary and partially palindromic or partially complementary single-stranded siRNAs. RNA Biol 2006, 3:82-89.
87. Saetrom P . Designing dual-targeting siRNA duplexes having two active strands that combine siRNA and microRNA-like targeting. Methods Mol Biol 2013, 942:169-177.
88. Anderson EM, Birmingham A, Baskerville S, Reynolds A, Maksimova E, Leake D, Fedorov Y, Karpilow J, Khvorova A . Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA 2008, 14:853-861.
89. Jackson AL, Linsley PS . Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010, 9:57-67.
90. Gantier MP, Tong S, Behlke MA, Irving AT, Lappas M, Nilsson UW, Latz E, McMillan NA, Williams BR . Rational design of immunostimulatory siRNAs. Mol Ther 2010, 18:785-795.
91. Eberle F, Giessler K, Deck C, Heeg K, Peter M, Richert C, Dalpke AH . Modifications in small interfering RNA that separate immunostimulation from RNA interference. J Immunol 2008, 180:3229-3237.
92. Cuccato G, Polynikis A, Siciliano V, Graziano M, di Bernardo M, di Bernardo D . Modeling RNA interference in mammalian cells. BMC Syst Biol 2011, 5:19.
93. Wei JX, Yang J, Sun JF, Jia LT, Zhang Y, Zhang HZ, Li X, Meng YL, Yao LB, Yang AG . Both strands of siRNA have potential to guide posttranscriptional gene silencing in mammalian cells. PLoS One 2009, 4:e5382.
94. Schwarz DS, Hutvagner G, Haley B, Zamore PD . Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol Cell 2002, 10:537-548.
95. Kenski DM, Willingham AT, Haringsma HJ, Li JJ, Flanagan WM . In vivo activity and duration of short interfering RNAs containing a synthetic 5'-phosphate. Nucleic Acid Ther 2012, 22:90-95.
96. Kawai T, Akira S . The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009, 21:317-337.
97. Robbins M, Judge A, MacLachlan I . siRNA and innate immunity. Oligonucleotides 2009, 19:89-102.
98. Sadler AJ, Williams BR . Interferon-inducible antiviral effectors. Nat Rev Immunol 2008, 8:559-568.
99. Gantier MP, Williams BR . The response of mammalian cells to double-stranded RNA. Cytokine Growth Factor Rev 2007, 18:363-371.
100. Uzri D, Gehrke L . Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. J Virol 2009, 83:4174-4184.
101. Peacock H, Fucini RV, Jayalath P, Ibarra-Soza JM, Haringsma HJ, Flanagan WM, Willingham A, Beal PA . Nucleobase and ribose modifications control immunostimulation by a microRNA-122-mimetic RNA. J Am Chem Soc 2011, 133:9200-9203.
102. Fucini RV, Haringsma HJ, Deng P, Flanagan WM, Willingham AT . Adenosine modification may be preferred for reducing siRNA immune stimulation. Nucleic Acid Ther 2012, 22:205-210.
103. Valenzuela RA, Suter SR, Ball-Jones AA, Ibarra-Soza JM, Zheng Y, Beal PA . Base modification strategies to modulate immune stimulation by an siRNA. Chembiochem 2015, 16:262-267.
104. Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, Kirschnek S, Gaffal E, Landsberg J, Hellmuth J, et al. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 2008, 14:1256-1263.
105. Ebert G, Poeck H, Lucifora J, Baschuk N, Esser K, Esposito I, Hartmann G, Protzer U . 5' Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology 2011, 141:696-706, 706.e1-3.
106. Han Q, Zhang C, Zhang J, Tian Z . Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner. Hepatology 2011, 54:1179-1189.
107. Chevalier C, Saulnier A, Benureau Y, Flechet D, Delgrange D, Colbere-Garapin F, Wychowski C, Martin A . Inhibition of hepatitis C virus infection in cell culture by small interfering RNAs. Mol Ther 2007, 15:1452-1462.
108. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, Lee H, Scuto A, Liu Y, Yang C, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009, 27:925-932.
109. Khairuddin N, Gantier MP, Blake SJ, Wu SY, Behlke MA, Williams BR, McMillan NA . siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol 2012, 90:187-196.
110. Meng G, Xia M, Xu C, Yuan D, Schnurr M, Wei J . Multifunctional antitumor molecule 5'-triphosphate siRNA combining glutaminase silencing and RIG-I activation. Int J Cancer 2014, 134:1958-1971.
111. Ellermeier J, Wei J, Duewell P, Hoves S, Stieg MR, Adunka T, Noerenberg D, Anders HJ, Mayr D, Poeck H, et al. Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res 2013, 73:1709-1720.
112. Schnurr M, Duewell P . Breaking tumor-induced immunosuppression with 5'-triphosphate siRNA silencing TGFβ and activating RIG-I. Oncoimmunology 2013, 2:e24170.
113. Anderson E, Boese Q, Khvorova A, Karpilow J . Identifying siRNA-induced off-targets by microarray analysis. Methods Mol Biol 2008, 442:45-63.
114. Dua P, Yoo JW, Kim S, Lee DK . Modified siRNA structure with a single nucleotide bulge overcomes conventional siRNA-mediated off-target silencing. Mol Ther 2011, 19:1676-1687.
115. Lee JB, Hong J, Bonner DK, Poon Z, Hammond PT . Self-assembled RNA interference microsponges for efficient siRNA delivery. Nat Mater 2012, 11:316-322.
116. van den Boorn JG, Dassler J, Coch C, Schlee M, Hartmann G . Exosomes as nucleic acid nanocarriers. Adv Drug Deliv Rev 2013, 65:331-335.
117. Kooijmans SA, Vader P, van Dommelen SM, van Solinge WW, Schiffelers RM . Exosome mimetics: a novel class of drug delivery systems. Int J Nanomedicine 2012, 7:1525-1541.
118. Ding Y, Wang Y, Zhou J, Gu X, Wang W, Liu C, Bao X, Wang C, Li Y, Zhang Q . Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis. Biomaterials 2014, 35:7214-7227.
119. Nakayama T, Butler JS, Sehgal A, Severgnini M, Racie T, Sharman J, Ding F, Morskaya SS, Brodsky J, Tchangov L, et al. Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles. Mol Ther 2012, 20:1582-1589.
120. Whitehead KA, Langer R, Anderson DG . Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129-138.
121. Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, Bannerjee SK . Drug delivery systems: an updated review. Int J Pharm Investig 2012, 2:2-11.
122. Kumar V, Qin J, Jiang Y, Duncan RG, Brigham B, Fishman S, Nair JK, Akinc A, Barros SA, Kasperkovitz PV . Shielding of lipid nanoparticles for siRNA delivery: impact on physicochemical properties, cytokine induction, and efficacy. Mol Ther Nucleic Acids 2014, 3:e210.
123. Shen H, Sun T, Ferrari M . Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther 2012, 19:367-373.
124. Nielsen C, Kjems J, Sorensen KR, Engelholm LH, Behrendt N . Advances in targeted delivery of small interfering RNA using simple bioconjugates. Expert Opin Drug Deliv 2014, 11:791-822.
125. Shete HK, Prabhu RH, Patravale VB . Endosomal escape: a bottleneck in intracellular delivery. J Nanosci Nanotechnol 2014, 14:460-474.
126. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO . Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.
127. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT . MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011, 13:423-433.